QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
Partnership is Latest in Series of RLS Efforts to Expand Industry-Leading CDMO Business and Clinical Trial Capability with Radiopharmaceutical Partners Across U.S.
Related news for (QSAM)
- QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
- QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
- QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
- QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
- QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center